Home›Articles›What Novo Nordisk has reported from the early trials of zenagamtideArticleWhat Novo Nordisk has reported from the early trials of zenagamtideArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnZenagamtide, Drugs and Medicinal Substances Well-attested SourcesZenagamtide (Wikipedia)Clinical trialsQuote, Clinical trialsIn January 2025, the company announced the results of its 1B/2A trial. The trial investigated safety, tolerability, and pharmacokinetics following weekly subcutaneous administration in 125 patients. Treatment duration was up to 36 weeks.View the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.